GlaxoSmithKline's (GSK.N) (GSK.L) Typherix vaccine shields children as young as 2 from typhoid fever, and widespread vaccination can even protect people who have not been given the shot, according to a study published on Wednesday. The test, conducted in two wards of an Indian slum where about 60,000 people live, was designed to see how well the Vi-type vaccin
e works in youngsters age 2 to 5. Doubt about its effectiveness in this younger age group is one reason the shots, which cost as little as 50 cents, are not widely given to prevent typhoid. The potentially deadly disease comes from contaminated food and water, and kills 216,000 to 600,000 people worldwide each year. At the end of 2004, 37,673 children and adults were inoculated with Typherix or, for comparison purposes, GlaxoSmithKline's Havrix vaccine for hepatitis A. Several companies make the typhoid vaccine. It worked in 61 percent of the people exposed to the disease, said the team led by Dr. Dipika Sur of the National Institute of Cholera and Enteric Diseases in Kolkata, India.
e works in youngsters age 2 to 5. Doubt about its effectiveness in this younger age group is one reason the shots, which cost as little as 50 cents, are not widely given to prevent typhoid. The potentially deadly disease comes from contaminated food and water, and kills 216,000 to 600,000 people worldwide each year. At the end of 2004, 37,673 children and adults were inoculated with Typherix or, for comparison purposes, GlaxoSmithKline's Havrix vaccine for hepatitis A. Several companies make the typhoid vaccine. It worked in 61 percent of the people exposed to the disease, said the team led by Dr. Dipika Sur of the National Institute of Cholera and Enteric Diseases in Kolkata, India.For Further Details Visit At:www.reuters.com/article/latestCrisis/idUSN22339312
No comments:
Post a Comment